Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis

Inflammatory bowel disease (IBD) is an umbrella term for two closely related but distinct chronic relapsing-remitting conditions: Crohn's disease (CD) and ulcerative colitis (UC). Both involve dysregulated immune activation against the gut microbiome in genetically susceptible individuals, causing chronic, often debilitating gut inflammation. A third category — IBD unclassified (IBDU) — is used when the distinction between CD and UC cannot be made.

IBD affects approximately 10 million people worldwide, with the highest prevalence in Western industrialised countries (Northern Europe, North America, Australia). Incidence is rising rapidly in East Asia — including China, Japan, and South Korea — as westernisation of diet and lifestyle alters the gut microbiome and immune programming. China's IBD caseload has grown approximately 10-fold over the past two decades.

IBD typically first presents in the teens to 30s (although a second peak occurs at 50–70), affects men and women equally, and follows a lifelong relapsing-remitting course. With effective modern management, most patients can achieve sustained remission and lead full lives.

Crohn's Disease vs Ulcerative Colitis

Feature	Crohn's Disease	Ulcerative Colitis
Location	Anywhere from mouth to anus; most commonly terminal ileum + colon	Colon only; always involves rectum; continuous proximal extension
Inflammation depth	Transmural (full thickness of bowel wall)	Mucosal only (superficial)
Pattern	Patchy, with skip lesions (normal bowel between affected segments)	Continuous, confluent
Strictures	Common (transmural fibrosis)	Rare
Fistulas/abscesses	Characteristic (transmural inflammation tracks through)	Very rare
Perianal disease	Common (fistulas, fissures, skin tags)	Rare
Smoking	Slightly increases risk; quitting worsens CD	Strongly protective against UC
Rectal bleeding	Variable	Universal hallmark
Surgery	Frequent (recurrence after surgery common)	Colectomy is curative

What Causes IBD?

IBD results from a complex interaction of genetic susceptibility, gut microbiome dysbiosis, environmental triggers, and dysregulated immune response:

Genetics: >200 genetic loci are associated with IBD susceptibility. Key genes affect innate immunity, autophagy (NOD2, ATG16L1), and epithelial barrier function. Having an affected first-degree relative increases IBD risk 4–10×.

Gut microbiome: IBD is associated with reduced gut bacterial diversity and specific microbial imbalances (dysbiosis). Particular bacterial species may trigger pathological immune activation in susceptible individuals.

Environmental factors: Westernised diet (high fat, refined carbohydrates, low fibre), antibiotic use in early life, C-section delivery, reduced childhood infections, urban living — all associated with increased IBD risk. These factors may alter the gut microbiome and immune education in early life.

Immune dysregulation: In IBD, T-helper cells (particularly Th1 and Th17 subsets) are inappropriately activated against gut antigens, driving persistent mucosal inflammation. This is why biological therapies that block specific immune pathways (TNF-α, IL-12/23, integrins) are so effective.

Symptoms

Ulcerative Colitis

• Rectal bleeding — the cardinal symptom; blood mixed with or coating the stool
• Diarrhoea — urgency, frequency (up to 20 motions/day in severe disease), tenesmus (sensation of incomplete evacuation)
• Lower abdominal cramping — particularly before defecation
• Disease extent determines severity: proctitis (rectum only) — bleeding with constipation; left-sided colitis — diarrhoea and bleeding; pancolitis — the most severe, systemic illness

Severe acute colitis (SAC) / fulminant colitis:

• ≥6 bloody stools/day + one of: fever, tachycardia, anaemia, or elevated ESR/CRP
• Requires hospitalisation; risk of toxic megacolon and colonic perforation — a surgical emergency

Crohn's Disease

Symptoms depend on disease location:

Ileocolonic Crohn's (most common):

• Right lower quadrant abdominal pain — may mimic appendicitis
• Diarrhoea (without blood if small bowel predominates; with blood if colonic)
• Weight loss — malabsorption (small bowel disease) + reduced intake
• Fatigue and anaemia

Colonic Crohn's: similar to UC — diarrhoea, bleeding, urgency

Upper GI Crohn's: nausea, vomiting, dysphagia, heartburn

Perianal Crohn's:

• Complex fistulas (connections between bowel and skin, vagina, or bladder)
• Anal fissures resistant to healing
• Perianal abscesses
• Skin tags around the anus
• Often painful and significantly impairs quality of life

Extraintestinal Manifestations (EIM)

Both CD and UC may affect organs outside the gut — in approximately 25–40% of patients:

• Joints: IBD-associated arthropathy (peripheral joint pains correlated with bowel activity; axial arthritis/sacroiliitis independent of bowel activity; ankylosing spondylitis)
• Eyes: uveitis, episcleritis (eye redness and pain)
• Skin: erythema nodosum (tender red nodules on shins); pyoderma gangrenosum (painful ulcers)
• Liver: primary sclerosing cholangitis (PSC) — almost exclusively in UC; progressive bile duct scarring; raises risk of cholangiocarcinoma and colorectal cancer

Diagnosis

Colonoscopy with Biopsies

The cornerstone of IBD diagnosis — allows direct visualisation of the mucosa, assessment of extent and activity, and tissue sampling. Colonoscopy in UC shows continuous erythema, loss of vascular pattern, granularity, and ulceration from the rectum proximally. Crohn's shows patchy inflammation, cobblestoning, deep ulcers, and skip lesions.

Histology on biopsies distinguishes IBD from infectious colitis and characterises the type. Granulomas (non-caseating) are pathognomonic of Crohn's disease.

MRI Enterography (MRE)

The preferred investigation for small bowel Crohn's disease — provides detailed imaging of the entire small bowel, assessing:

• Location and extent of active inflammation (mural thickening, mucosal hyperenhancement)
• Complications: strictures, abscesses, fistulas
• Perianal disease (pelvic MRI)

No radiation exposure — important as IBD is a lifelong disease requiring repeated imaging.

Laboratory Markers

• CRP and ESR — elevated during active disease; guide treatment response
• Faecal calprotectin — a sensitive marker of gut inflammation; guides endoscopy decisions and monitors disease activity non-invasively; normal (<50 µg/g): remission; elevated (>200 µg/g): active inflammation
• FBC: anaemia (blood loss, chronic disease, B12/folate deficiency in ileal CD), leucocytosis, thrombocytosis
• Albumin: low in active disease — reflects protein loss and inflammation
• IBD serology (ASCA, ANCA): moderate diagnostic utility for differentiating CD from UC; not used in isolation

Stool Cultures

All patients with new diarrhoea must have stool cultures, C. difficile testing, and parasitology to exclude infection before starting IBD treatment.

Treatment

Treatment aims are: inducing and maintaining remission; preventing complications (strictures, fistulas, cancer); minimising steroid use; and improving quality of life.

5-Aminosalicylic Acid (5-ASA / Mesalazine)

First-line treatment for mild-to-moderate UC — reduces mucosal inflammation in the colon by inhibiting prostaglandin synthesis and NFκB signalling. Administered orally (Pentasa, Salofalk) and/or topically (rectal foam or suppository for proctitis/left-sided disease). 5-ASA also reduces colorectal cancer risk in UC.

5-ASA is not effective in Crohn's disease — should not be used.

Corticosteroids

For induction of remission in moderate-to-severe UC and CD flares:

• Oral prednisolone: typically 40 mg/day tapering over 8–12 weeks; effective for rapid symptom control; not suitable for maintenance (bone loss, metabolic effects, adrenal suppression)
• IV hydrocortisone or methylprednisolone: for severe/hospitalised flares
• Budesonide (Entocort): locally acting steroid; minimal systemic absorption; preferred for ileocaecal CD or UC with right-sided extension

Prolonged steroid use or steroid dependence mandates escalation to steroid-sparing therapies.

Immunomodulators

For maintenance of remission — steroid-sparing agents:

• Azathioprine / 6-mercaptopurine: inhibit purine synthesis in lymphocytes; effective maintenance therapy in both CD and UC; onset of action 3–6 months; risk of myelosuppression and lymphoma with long-term use; check TPMT enzyme before starting
• Methotrexate: used in CD; effective maintenance; contraindicated in pregnancy

Biological Therapies

A major advance in IBD treatment — targeted monoclonal antibodies against specific inflammatory pathways:

Anti-TNF agents:

• Infliximab (Remicade/Remsima) — IV infusion every 8 weeks after induction; effective for moderate-to-severe CD and UC; first-line biologic in many guidelines; also effective for perianal fistulas
• Adalimumab (Humira/Hyrimoz) — subcutaneous fortnightly injection; comparable efficacy; convenient for home administration
• Certolizumab pegol — SC injection; used in CD; pegylated fragment; safe in pregnancy

Anti-integrin:

• Vedolizumab (Entyvio) — IV or SC; selective for the gut (blocks lymphocyte trafficking into gut mucosa via α4β7 integrin); gut-selective with favourable safety profile; effective in both CD and UC; preferred in elderly or immunocompromised patients where anti-TNF infection risk is a concern

Anti-IL-12/23:

• Ustekinumab (Stelara) — IV loading dose then SC every 8–12 weeks; targets IL-12 and IL-23 (Th1 and Th17 pathway); effective in CD and UC; excellent safety profile; low immunogenicity

Small molecule (JAK inhibitors) — oral:

• Tofacitinib (Xeljanz) — oral twice daily; licensed for UC; rapid onset; risk of thromboembolism and herpes zoster; not for CD
• Upadacitinib (Rinvoq) — selective JAK1 inhibitor; approved for both CD and UC; highest efficacy oral agent; once daily tablet; monitoring required

Combination therapy (anti-TNF + azathioprine/methotrexate) is more effective than monotherapy for induction and maintenance — reduces anti-drug antibody formation.

Surgery

Ulcerative Colitis:
Proctocolectomy (removal of the entire colon and rectum) is curative — UC affects only the colon. Surgery is indicated for:

• Acute severe colitis not responding to medical therapy (toxic megacolon/perforation: emergency surgery)
• Medically refractory disease
• High-grade dysplasia or cancer
• Elective patient choice

The preferred reconstruction is restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA/"J-pouch") — creating a reservoir from the terminal ileum attached to the anus; preserves continence. Performed laparoscopically in most centres.

Crohn's Disease:
Surgery in CD treats complications (strictures causing obstruction, fistulas, abscesses) but does not cure the underlying disease — Crohn's recurs at the anastomosis. Principles:

• Bowel-sparing surgery — resect as little as possible; short strictureplasty for short fibrous strictures rather than resection
• Drainage of abscesses (often CT-guided) before definitive surgery
• EUA (examination under anaesthesia) for complex perianal fistulas; loose seton drainage to control sepsis before definitive repair; anti-TNF biologics combined with surgical repair for perianal fistulas

IBD Care in China

China's gastroenterology and IBD centres offer:

• Comprehensive IBD diagnosis: high-definition colonoscopy with biopsies, MRI enterography, faecal calprotectin, and full serological and microbiological panel
• Full biological therapy access: infliximab, adalimumab, vedolizumab, and ustekinumab — including Chinese biosimilar versions; tofacitinib and upadacitinib available
• Infliximab drug level monitoring: therapeutic drug monitoring (TDM) guided dose optimisation — reduces loss of response and guides switching decisions
• Laparoscopic colectomy and J-pouch surgery: experienced colorectal surgeons for IBD-related surgery; minimally invasive approach standard
• Perianal Crohn's management: combined medical and surgical approach with EUA, seton insertion, and biologic therapy
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from diagnosis through biological therapy and surgical planning

Contact a ChinaMedicalTour care navigator to arrange an IBD assessment, colonoscopy, or biological therapy consultation.

---

Medical content based on MSD Manuals and international IBD guidelines (ECCO, AGA, NICE). Evidence reviewed 2025.

Frequently Asked Questions

Can overseas patients submit endoscopic or imaging reports for digestive condition review?

Yes. Endoscopy reports, abdominal ultrasound, CT, or MRI scans can be reviewed by Chinese gastroenterologists to evaluate diagnostic workups and therapeutic strategies before traveling.

What digestive diagnostic and therapeutic procedures are available in Chinese hospitals?

Tertiary digestive endoscopy centers offer high-definition chromoendoscopy, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), capsule endoscopy, and multidisciplinary IBD management.

How are digestive consultations and procedures arranged for international visitors?

Outpatient specialist consultations, bowel preparation coordination, and day surgery or inpatient bookings are confirmed directly with participating tertiary hospital departments.